Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SCYX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSCYNEXIS raises $40M in dilutive private placement, issues 43.5M shares plus 43.5M warrants
Filed March 31, 2026 · Period ending March 30, 2026 · ~1 min read
Key Changes
-
high
Company sold 43.5M shares/pre-funded warrants at $0.92 each for ~$40M gross proceeds, representing significant dilution to existing shareholders. CEO participated in the offering.
Item 1.01 verify on EDGAR → -
high
Issued warrants to buy 43.5M additional shares at $1.20 (30% above offering price), exercisable only after shareholder approval and expiring 30 days after Phase 2 kidney disease trial data or 5 years.
Item 1.01 verify on EDGAR → -
high
Cash runway extended into mid-2029 with new proceeds (excluding warrant exercises), reducing near-term financing risk but at cost of substantial shareholder dilution.
Item 8.01 verify on EDGAR → -
medium
Must hold shareholder vote within 90 days to authorize additional shares for warrant exercises. Failure would block up to $52M in potential additional proceeds and strand warrant holders.
Item 1.01 verify on EDGAR → -
medium
Required to register shares for resale within 30 days and have registration effective within 75 days, creating near-term selling pressure once institutional investors gain liquidity.
Item 1.01 verify on EDGAR →
Summary
SCYNEXIS completed a $40 million private placement that will substantially dilute existing shareholders. The company sold 43.5 million shares and pre-funded warrants at $0.92 per unit—each accompanied by a warrant to buy another share at $1.20. If all warrants are exercised, total dilution could reach 87 million shares, nearly doubling the float depending on current share count.
The warrant structure is unusual: they expire just 30 days after the company releases Phase 2 data for its kidney disease drug SCY-770, creating urgency around that clinical readout. For retail holders, the immediate impact is dilution at $0.92 per share. The extended cash runway into mid-2029 removes near-term bankruptcy risk, but at a steep price.
Watch for two catalysts: the shareholder vote (required within 90 days) to authorize the warrant shares, and the registration statement (due within 30 days) that will allow institutional investors to sell freely. Both events could pressure the stock. The warrant expiration tied to clinical data is a double-edged sword—it incentivizes the company to release results, but also creates a ticking clock for warrant holders that could drive volatility around the Phase 2 readout.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
SCYNEXIS raised ~$40M via private placement of 34.75M shares and 8.75M pre-funded warrants at $0.92, plus warrants for 43.5M additional shares at $1.20.
Added in current filing · verify on EDGAR →
On March 30, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain new and existing institutional and accredited investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) 34,750,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 8,750,000 shares of Common Stock and (iii) accompanying common warrants (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”) to purchase up to an aggregate of 43,500,000 shares of Common Stock or Pre-Funded Warrants.
SCYNEXIS entered into a private placement agreement to sell 34.75 million common shares and 8.75 million pre-funded warrants, each accompanied by common warrants to purchase an additional 43.5 million shares. The company expects to raise approximately $40 million in gross proceeds before fees, with potential for an additional $52.2 million if all warrants are exercised for cash. The CEO participated in the offering, purchasing 108,695 shares with accompanying warrants.
Added in current filing · verify on EDGAR →
34,750,000 Shares and accompanying Common Warrants were sold at a combined price of $0.92 per Share and accompanying Common Warrant, and 8,750,000 Pre-Funded Warrants and accompanying Common Warrants were sold at a combined price of $0.9199 per Pre-Funded Warrant and accompanying Common Warrant.
The offering was priced at $0.92 per share with accompanying warrant, representing the pricing at which institutional and accredited investors purchased equity. The pre-funded warrants were priced at $0.9199 (essentially the same price minus the $0.0001 exercise price). This pricing will determine the immediate dilution to existing shareholders and sets a reference point for near-term stock valuation.
Added in current filing · verify on EDGAR →
Pursuant to the terms of the Registration Rights Agreement, the Company is obligated to prepare and file with the Securities and Exchange Commission (“SEC”) a registration statement (the “Registration Statement”) to register for resale of the Registrable Securities within 30 days of the closing date of the Private Placement and to use its reasonable best efforts to have the Registration Statement declared effective as soon as possible, but no later than 75 days after the initial filing date of the Registration Statement, subject to extension under the terms of the Registration Rights Agreement.
SCYNEXIS must file a registration statement within 30 days and have it declared effective within 75 days to allow investors to resell their shares. This creates near-term selling pressure once the registration becomes effective, as institutional investors typically seek liquidity. The company is obligated to maintain the registration until shares can be sold freely under Rule 144.
Event · Item 3.02 — Unregistered Sales of Equity Securities
SCYNEXIS completed a private placement of shares and warrants under Section 4(a)(2) exemption without registration.
Added in current filing · verify on EDGAR →
The Shares and Warrants have not been registered under the Securities Act, in reliance on the exemption from registration afforded by Section 4(a) (2) of the Securities Act.
SCYNEXIS sold unregistered shares and warrants in a private placement transaction using the Section 4(a)(2) exemption from Securities Act registration. This means the securities were sold to a limited group of investors without public offering or general solicitation. The company references additional details in Item 1.01 of this filing.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Each of the Investors has provided representations appropriate for a private placement of securities. The sale of the Shares and the Warrants did not involve a public offering and was made without general solicitation or general advertising.
The investors in this private placement provided appropriate representations confirming their eligibility to participate in a non-public offering. The transaction was conducted without any public solicitation or advertising, which is required to maintain the Section 4(a)(2) exemption status.
Event · Item 7.01 — Regulation FD Disclosure
SCYNEXIS announced a private placement financing via press release under Regulation FD.
Added in current filing · verify on EDGAR →
On March 31, 2026, the Company issued a press release announcing the Private Placement.
SCYNEXIS disclosed a private placement financing transaction through a press release. The 8-K references the press release as Exhibit 99.1 but does not provide details on the size, terms, or investors involved. This is a Regulation FD disclosure, meaning material information is being publicly released to ensure fair access.
Event · Item 8.01 — Other Events
SCYNEXIS estimates cash runway into mid-2029 with anticipated proceeds from a private placement.
Added in current filing · verify on EDGAR →
Based on its current plans, the Company estimates that its existing cash, cash equivalents and marketable securities, together with the anticipated net proceeds from the Private Placement (excluding potential proceeds from the exercise of any Common Warrants), will be sufficient to fund its operations into mid-2029.
The company disclosed that its current cash resources plus expected proceeds from a private placement will fund operations into mid-2029. This provides investors visibility into the company's financial runway and reduces near-term dilution or financing concerns. The guidance excludes any additional proceeds from warrant exercises, making it a conservative estimate.
Event · Item 9.01 — Financial Statements and Exhibits
SCYNEXIS filed exhibits for securities purchase agreements, warrants, and registration rights, likely related to a capital raise.
Added in current filing · verify on EDGAR →
Exhibit No. | Description | 4.1 | Form of Pre-Funded Warrant | 4.2 | Form of Common Warrant | 10.1 | Form of Securities Purchase Agreement | 10.2 | Form of Registration Rights Agreement | 99.1
Press release of the Company dated March 31, 2026
The company filed forms for pre-funded warrants, common warrants, a securities purchase agreement, and registration rights agreement. These documents typically accompany a private placement or registered direct offering to raise capital. A press release dated the same day likely contains details about the transaction terms and proceeds.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify